Sara Piccinelli, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 5 | 2024 | 2210 | 0.730 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 5753 | 0.290 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2024 | 1510 | 0.230 |
Why?
|
| Interleukin-15 | 1 | 2024 | 186 | 0.210 |
Why?
|
| Graft vs Host Disease | 3 | 2021 | 3078 | 0.200 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2019 | 122 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 1365 | 0.150 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 827 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 347 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2023 | 1343 | 0.130 |
Why?
|
| Transplantation Conditioning | 2 | 2021 | 1635 | 0.130 |
Why?
|
| Immune System Diseases | 1 | 2018 | 251 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 778 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 3646 | 0.110 |
Why?
|
| Neoplasms | 1 | 2023 | 22340 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2023 | 1597 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1927 | 0.100 |
Why?
|
| Leukemia | 1 | 2019 | 1522 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2022 | 1539 | 0.090 |
Why?
|
| Italy | 2 | 2023 | 854 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3946 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2019 | 3111 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2023 | 4752 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 5197 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 4348 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2024 | 13039 | 0.070 |
Why?
|
| Hepatitis C Antibodies | 1 | 2023 | 151 | 0.050 |
Why?
|
| K562 Cells | 1 | 2024 | 649 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 404 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2024 | 1347 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2022 | 574 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 2021 | 438 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2022 | 267 | 0.040 |
Why?
|
| Cytokines | 2 | 2024 | 7421 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 2228 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2024 | 1375 | 0.040 |
Why?
|
| Humans | 12 | 2024 | 765968 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2019 | 547 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2023 | 2864 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 10261 | 0.030 |
Why?
|
| Overweight | 1 | 2024 | 2444 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 8041 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 1624 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 4860 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3888 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3426 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3390 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 3925 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 17075 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 223009 | 0.020 |
Why?
|
| Mass Screening | 1 | 2023 | 5446 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 54802 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15842 | 0.020 |
Why?
|
| Aged | 3 | 2024 | 171117 | 0.020 |
Why?
|
| Adult | 3 | 2023 | 223044 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8703 | 0.010 |
Why?
|
| Obesity | 1 | 2024 | 13076 | 0.010 |
Why?
|
| Male | 3 | 2024 | 363698 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 59489 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 168764 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23601 | 0.010 |
Why?
|
| Young Adult | 1 | 2022 | 59889 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 88835 | 0.010 |
Why?
|
| Female | 2 | 2023 | 396112 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 74840 | 0.010 |
Why?
|